Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. MU
6. FDX
7. IBM
8. PRIM
9. PFE
10. AWK

Go back to Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics (CARA) FV Target Raised to $33 at Janney

May 29, 2019 3:40 PM EDT

Janney analyst Esther Hong raised the fair value target on Cara Therapeutics (NASDAQ: CARA) to $33.00 (from $27.00) while maintaining a Buy rating following data.

The analyst commented, "Today's announcement of positive Ph.3 KALM-1 IV-Korsuva data demonstrating statistical significance on the primary and all... More

Cara Therapeutics (CARA) PT Raised to $28 at H.C. Wainwright

May 29, 2019 10:55 AM EDT

H.C. Wainwright analyst Oren Livnat raised the price target on Cara Therapeutics (NASDAQ: CARA) to $28.00 (from $26.00) while maintaining a Buy rating.

... More

Stifel Reiterates Buy Rating on Cara Therapeutics (CARA)

May 29, 2019 8:23 AM EDT

Stifel analyst Annabel Samimy reiterated a Buy rating and $26.00 price target on Cara Therapeutics (NASDAQ: CARA) following positive top-line data from the first pivotal study (KALM-1) of IV-Korsuva in pruritus associated with chronic kidney disease (CKD-aP) in hemodialysis patients.

The study met its... More

Cara Therapeutics (CARA) to Resume Trading at 7:30 am ET

May 29, 2019 7:04 AM EDT

Cara Therapeutics (NASDAQ: CARA) to Resume Trading at 7:30 am ET

... More